<?xml version="1.0" encoding="UTF-8"?>
<p>Glucocorticoids have been commonly used in patients with SARS-CoV or MERS-CoV infection [
 <xref rid="B74" ref-type="bibr">74</xref>,
 <xref rid="B75" ref-type="bibr">75</xref>]. Glucocorticoids prolonged the survival time of SARS cases [
 <xref rid="B75" ref-type="bibr">75</xref>]. Patients with COVID-19 were given glucocorticoids in some hospitals in China. However, the mortality rate did not decrease with corticosteroid treatment in patients infected with SARS-CoV-2, and viral clearance was not delayed [
 <xref rid="B6" ref-type="bibr">6</xref>,
 <xref rid="B74" ref-type="bibr">74</xref>]. Therefore, it is still controversial whether corticosteroids should be used to treat SARS-CoV-2 infections [
 <xref rid="B69" ref-type="bibr">69</xref>].
</p>
